The role of thymidine kinase in cancer diseases.
暂无分享,去创建一个
[1] H. Vesselle,et al. A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors. , 2007, Nuclear medicine and biology.
[2] J. Finek,et al. Tumor markers in patients with relapse of colorectal carcinoma. , 2007, Anticancer research.
[3] O. Topolcan,et al. Prognostic importance of thymidine kinase in colorectal and breast cancer. , 2007, Anticancer research.
[4] O. Topolcan,et al. Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases. , 2007, Anticancer research.
[5] T. Hájek,et al. Tumor markers in pleural effusions. , 2007, Anticancer research.
[6] O. Topolcan,et al. Changes of serum thymidine kinase in children with acute leukemia. , 2007, Anticancer research.
[7] M. Duffy,et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.
[8] N. Sardesai,et al. Detection of Newly Diagnosed Bladder Cancer, Bladder Cancer Recurrence and Bladder Cancer in Patients with Hematuria Using Quantitative RT-PCR of Urinary Survivin , 2007, Tumor Biology.
[9] M. Abrahamowicz,et al. Disability Evolution in Multiple Sclerosis: How to Deal with Missing Transition Times in the Markov Model? , 2007, Neuroepidemiology.
[10] H. Johansson,et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. , 2006, Anticancer research.
[11] K. Itoh,et al. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[12] M. Piccart,et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. , 2006, The oncologist.
[13] Wei Zhang,et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. , 2006, Oncology reports.
[14] R. Lamerz,et al. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. , 2005, Anticancer research.
[15] L. Holubec,et al. TPS, thymidine kinase, VEGF and endostatin in cytosol of thyroid tissue samples. , 2005, Anticancer research.
[16] Staffan Eriksson,et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. , 2005, Oncology reports.
[17] J. Castro,et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. , 2004, International journal of oncology.
[18] Staffan Eriksson,et al. Sensitive nonradiometric method for determining thymidine kinase 1 activity. , 2004, Clinical chemistry.
[19] R. González-Sarmiento,et al. Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancer , 2003, International journal of cancer.
[20] Seung-Ha Park,et al. The Relationship between Serum VEGF Concentration and Prognosis of Lung Cancer , 2003, The Korean journal of internal medicine.
[21] Otakar Belohlavek,et al. Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making , 2003 .
[22] M. Rocchi,et al. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. , 2003, The International journal of biological markers.
[23] C. Coca,et al. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. , 2003, Anticancer research.
[24] H. Kimura,et al. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. , 2003, Anticancer research.
[25] M. Kersten,et al. Serum Soluble CD27, but Not Thymidine Kinase, Is an Independent Prognostic Factor for Outcome in Indolent Non-Hodgkin’s Lymphoma , 2003, Tumor Biology.
[26] C. Tei,et al. Clinical significance of serum neuron‐specific enolase in patients with adult T‐cell leukemia , 2002, American journal of hematology.
[27] H. Katabuchi,et al. Thymidine kinase in epithelial ovarian cancer: Relationship with the other pyrimidine pathway enzymes , 2002, International journal of cancer.
[28] L Zou,et al. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. , 2002, The International journal of biological markers.
[29] B. K. Murray,et al. Thymidine kinase: diagnostic and prognostic potential , 2001, Expert review of molecular diagnostics.
[30] H. Yeh,et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] H. Katabuchi,et al. Clinical Value of Thymidine Kinase in Patients with Cervical Carcinoma , 2001, Oncology.
[32] B Asselain,et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Kantarjian,et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] J. Foekens,et al. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. , 2001, Cancer research.
[35] K. O’Neill,et al. A monoclonal antibody specific for human thymidine kinase 1. , 2001, Hybridoma.
[36] S. Eriksson,et al. Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1 , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[37] O. Topolcan,et al. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. , 2000, Anticancer research.
[38] S. Eriksson,et al. Cloning and characterization of full-length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. , 2000, The Biochemical journal.
[39] J. Berek,et al. Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.
[40] T. Fornander,et al. The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody , 2000, The International journal of biological markers.
[41] E. Thiel,et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.
[42] S. Barnhill,et al. CA 125: The past and the Future , 1998, The International journal of biological markers.
[43] D. Dormont,et al. Monitoring of intracellular levels of 5'-monophosphate-AZT using an enzyme immunoassay. , 1998, Journal of immunological methods.
[44] M A Torkington,et al. An evidence-based approach , 1998, British Dental Journal.
[45] L. Kanz,et al. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.
[46] M. Hallek,et al. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. , 1997, Clinica chimica acta; international journal of clinical chemistry.
[47] H. Pahl,et al. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. , 1997, Anticancer research.
[48] G. Sutton,et al. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. , 1997, Anticancer research.
[49] J. Foekens,et al. DNA‐synthesis enzyme activity: A biological tool useful for predicting anti‐metabolic drug sensitivity in breast cancer? , 1997, International journal of cancer.
[50] E. Wintersberger. Regulation and biological function of thymidine kinase. , 1997, Biochemical Society transactions.
[51] M. Hallek,et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.
[52] J. Robertson,et al. Serum thymidine kinase in colorectal neoplasia. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[53] S. Modoni,et al. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia , 1995, British journal of haematology.
[54] O. Chinot,et al. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer , 1995, International journal of cancer.
[55] B. Munch‐Petersen,et al. Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. , 1994, Leukemia research.
[56] J. Borovanský,et al. Thymidine kinase in malignant melanoma , 1994, Melanoma research.
[57] E. Wintersberger,et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.
[58] T. Aotake,et al. [Prediction of prognosis of patients with gastrointestinal cancer based on thymidine uptake]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.
[59] F. Naguib,et al. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. , 1993, Cancer research.
[60] B. Munch‐Petersen,et al. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. , 1993, The Journal of biological chemistry.
[61] Duen-Yi Huang,et al. The regulation of thymidine kinase in HL-60 human promyeloleukemia cells. , 1993, The Journal of biological chemistry.
[62] K. O’Neill,et al. Can thymidine kinase levels in breast tumors predict disease recurrence? , 1992, Journal of the National Cancer Institute.
[63] F. Spyratos,et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. , 1992, Journal of the National Cancer Institute.
[64] B. Emmerich,et al. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications , 1992, Annals of Hematology.
[65] Kauffman Mg,et al. Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (G0) cells. , 1991 .
[66] P. Lönnroth,et al. Amiloride inhibits insulin sensitivity and responsiveness in rat adipocytes through different mechanisms. , 1991, Biochemical and biophysical research communications.
[67] T. Kelly,et al. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.
[68] B. Oberg,et al. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.
[69] A. S. Lee,et al. Identification of a 70-base-pair cell cycle regulatory unit within the promoter of the human thymidine kinase gene and its interaction with cellular factors , 1991, Molecular and cellular biology.
[70] S. Conrad,et al. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. , 1990, The Journal of biological chemistry.
[71] J. Gronowitz,et al. Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA , 1990, Molecular and Cellular Biochemistry.
[72] G. Merrill,et al. Thymidine kinase synthesis is repressed in nonreplicating muscle cells by a translational mechanism that does not affect the polysomal distribution of thymidine kinase mRNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[73] M. Meuth,et al. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. , 1989, Experimental cell research.
[74] F. Ruddle,et al. Transcriptional and posttranscriptional mechanisms regulate murine thymidine kinase gene expression in serum-stimulated cells , 1988, Molecular and cellular biology.
[75] D. Sheer,et al. Construction of a genetic map of human chromosome 17 by use of chromosome-mediated gene transfer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[76] M. Hallek,et al. Activity of serum thymidine kinase in non-Hodgkin lymphoma: Relationship to other prognostic factors , 1988, Klinische Wochenschrift.
[77] D. Macphee,et al. The role of blood platelets in nucleoside metabolism: assay, cellular location and significance of thymidine phosphorylase in human blood. , 1988, Mutation research.
[78] J. Kausitz. [Radioimmunoanalysis in oncology]. , 1988, Bratislavske lekarske listy.
[79] J. Sherley,et al. Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.
[80] J. Sherley,et al. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. , 1988, The Journal of biological chemistry.
[81] D. L. Coppock,et al. Control of thymidine kinase mRNA during the cell cycle , 1987, Molecular and cellular biology.
[82] K. Nilsson,et al. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia , 1987, European journal of haematology.
[83] Broder,et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[84] B Simonsson,et al. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia , 1984, Cancer.
[85] B. Munch‐Petersen. Differences in the kinetic properties of thymidine kinase isoenzymes in unstimulated and phytohemagglutinin-stimulated human lymphocytes , 1984, Molecular and Cellular Biochemistry.
[86] H. Hagberg,et al. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. , 1983, British Journal of Cancer.
[87] Y. Cheng,et al. Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. , 1976, The Journal of biological chemistry.
[88] B. Barbiroli,et al. Thymidine kinase and deoxyribonucleic acid metabolism in growing and regenerating livers from rats on controlled feeding schedules. , 1973, The Biochemical journal.
[89] O. Jones,et al. Properties of thymidine kinase partially purified from human fetal and adult tissue. , 1972, The Journal of biological chemistry.
[90] N. Fukui. Factors regulating thymidine kinase in regenerating liver. , 1971, Journal of biochemistry.
[91] Enrique Parás Chavero. The past and the future , 1965 .
[92] E. Kay,et al. An Improved Preparation of Sodium Desoxyribonucleate , 1952 .
[93] A. Chang. Oncology : an evidence-based approach , 2006 .
[94] S. Skog,et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. , 2005, Oncology reports.
[95] O. Belohlávek,et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[96] S. Tucker,et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. , 1995, Leukemia & lymphoma.
[97] T. Kelly,et al. Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (G0) cells. , 1991, Oncogene.
[98] P. McKenna,et al. The Significance of Thymidine Kinase in Determining Resistance to Mutagenesis in Friend Mouse Leukemia Cells , 1991 .
[99] S. Tadepalli,et al. Determination of zidovudine concentration in serum by enzyme-linked immunosorbent assay and by time-resolved fluoroimmunoassay. , 1990, Journal of acquired immune deficiency syndromes.
[100] P. Roberts. Tumour markers in colorectal cancer. , 1988, Scandinavian journal of gastroenterology. Supplement.
[101] P. Reichard,et al. Reduction of ribonucleotides. , 1979, Annual review of biochemistry.
[102] A. Kornberg,et al. DEOXYTHYMIDINE KINASE OF ESCHERICHIA COLI. II. KINETICS AND FEEDBACK CONTROL. , 1964, The Journal of biological chemistry.